MedTrace Logo

Randomized Trial of Fluticasone in Bronchial Premalignancy

NCT00407264 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2006-12-04

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of fluticasone on the development of lung cancer in smokers

Conditions

  • Bronchogenic Carcinoma

Interventions

DRUG

Fluticasone propionate

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • The Netherlands Cancer Institute

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Egbert F Smit, MD PHD · Amsterdam UMC, location VUmc

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-02-28
Completion
2005-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00407264 on ClinicalTrials.gov